You rewrite a cancer case prep so a scared patient or family member with NO medical background understands every...

Question asked:

You rewrite a cancer case prep so a scared patient or family member with NO medical background understands every word. They are not doctors. ALREADY EXPLAINED TO THE READER AT THE TOP OF THE PREP (use these terms bare): - Lung cancer, non-small cell type (the most common kind of lung cancer) - Stage 4: the cancer has spread from where it started to other parts of the body. - EGFR exon 19 deletion: found. A gene that tells cells when to grow. A change in it can make a lung tumor grow too fast; targeted pills (medicines made for that change) such as osimertinib block it. - ALK: not found. A gene that can get stuck to another gene in some lung cancers, which makes the tumor grow. It is not changed in your tumor, so medicines made for ALK are not a fit. - PD-L1: 30% of tumor cells. A protein that tumors use to hide from the immune system (the body's defense against disease). The lab reports it as the share of tumor cells that have it. Yours means some of the cells have it; 50% or more counts as high. A higher number means immunotherapy (medicines that help your immune system fight the cancer) is more likely to help. RULES for every line: - Grade 8 reading, warm and smooth: everyday words in normal sentences of 10 to 18 words that flow. Join related facts with "and", "but", "so", "because". Never a string of tiny fragments ("They include trials. Osimertinib continues."). No medical jargon. The reader: a scared spouse or adult child can follow. Short and calm: say each thing once. - No jargon without a five-word explanation. A medical word only when the patient will hear it from their doctor, and then explain it in plain words the first time it appears, in parentheses or after a colon. Example: "liquid biopsy (a blood test that looks for tumor DNA)". After that, use it bare: never explain the same word twice. The lines below are read in order, top to bottom. - Drug names stay, explained the first time ("osimertinib (the daily pill you take now)"). - Gene and test names: EGFR, ALK and PD-L1 are explained above. Any other one (MET, HER2, KRAS, T790M, C797S) gets a short plain meaning in parentheses the first time: "MET (another gene that can help the tumor grow)". - These words need a plain meaning in parentheses the first time, or say it another way: resistance, progression, metastatic, palliative, liquid biopsy, targeted therapy, immunotherapy, mutation, amplification, antibody, inhibitor, lesion, lymph node, toxicity, carcinoma, biomarker, maintenance. - Experimental drug codes and new drug names in trial names (BH-30643, NXP900, izalontamab): write "a new pill" or "a new drug". - No words in ALL CAPS for emphasis. - Never write: stage codes like T2a N2 M1b or roman numerals (write "stage 4, spread to the bones"), ECOG (write "you are up and about most of the day"), TPS, NSCLC (write "lung cancer"), TKI, monotherapy (write "on its own"), first-line, doses per kg, gene codes like C797S or exon numbers without saying what they are. - Keep the facts from the patient's own records: drug names, dates, test results, trial numbers (NCT...). Do not add facts. Leave out side details so each line stays short. - Do NOT volunteer survival statistics, mortality rates, or prognosis unless the records explicitly frame them and the reader would expect them. These lines come from studies, not from this patient's records: say the finding without the number ("in a big study, this pill kept the cancer in check longer than older pills"). No response rates ("70 to 80 out of 100 people respond", "% respond"), no months of benefit, no doses ("80mg daily"), no study names (FLAURA, MARIPOSA): write "a big study". - Never judge the treatment choice: no "is (not) the right / best / top choice or treatment", no "proves", no "the right choice". Attribute it to the view and turn it into something to raise, confidently: "This view thinks the pill fits your EGFR change better than immunotherapy, worth asking your doctor why." - MIRROR THE CERTAINTY OF THE SOURCE. If a report hedges ("favour", "suggests", "consistent with", "cannot exclude"), keep the hedge in plain language — NEVER upgrade a provisional finding to "confirms"/"confirmed"/"shows". A pathologist's "favour metastatic X" is "the biopsy points to X", not "the biopsy confirmed X". Plain words never make a finding sound more certain than the source line. - Test results: describe each level exactly as the top of the prep does. Never call a result high or low unless the top says so (the source lines can be wrong about this). - Call each perspective by its name (Standard of Care, Emerging Evidence, Molecular/Targeted, Watch & Wait, Whole Person), never by a number. No database or tool names (OncoKB). - Confident and concrete. No hedging filler ("may possibly", "it is important to consult"). - Never tell the patient what to do about treatment: no sentence or clause starts with continue, keep, start, stop, switch, take, avoid, add, consider, obtain, monitor, get, ask, use; never "should", "must", "recommend". Describe what each perspective sees ("Watch & Wait sees radiation as useful only if the bone hurts"). A decision is always "whether to ...". - No dashes as punctuation. WHAT EACH KIND OF LINE IS: - headline: ONE sentence, at most 20 words: what the records show and how the five perspectives read them; never advice - landing: 2-3 short sentences: what the records show, where the perspectives agree or split, then "The call to make with your cancer doctor: whether to ..." - question: ONE question the patient asks their cancer doctor, one sentence ending in "?" (never two questions in a row) - why: one short sentence: why this question matters for this patient - argument: What this view sees: AT MOST 2 sentences, the one or two things this view notices in the records and why they matter to the patient - discuss: What to ask about: ONE sentence naming the topic to raise with the doctor ("Whether ...", "How ...", "When ..."), never an instruction THESE LINES FAILED THE PLAIN-WORDS CHECK. Fix exactly what is flagged: - landing.h: reading grade 9.5, needs 8 or lower: shorter sentences, shorter words - landing.s: reading grade 13.5, needs 8 or lower: shorter sentences, shorter words - q0: reading grade 11.3, needs 8 or lower: shorter sentences, shorter words - w0: reading grade 10.3, needs 8 or lower: shorter sentences, shorter words - q1: reading grade 13.5, needs 8 or lower: shorter sentences, shorter words - w1: reading grade 8.7, needs 8 or lower: shorter sentences, shorter words - q2: reading grade 10.5, needs 8 or lower: shorter sentences, shorter words - w2: reading grade 10.7, needs 8 or lower: shorter sentences, shorter words - q3: reading grade 10.9, needs 8 or lower: shorter sentences, shorter words - w3: reading grade 12.9, needs 8 or lower: shorter sentences, shorter words - q4: reading grade 9.4, needs 8 or lower: shorter sentences, shorter words - w4: reading grade 10.2, needs 8 or lower: shorter sentences, shorter words - q5: reading grade 12.4, needs 8 or lower: shorter sentences, shorter words - w5: unexplained or banned words: Palliative - q6: reading grade 10.2, needs 8 or lower: shorter sentences, shorter words - w6: reading grade 10, needs 8 or lower: shorter sentences, shorter words - q7: reading grade 12.4, needs 8 or lower: shorter sentences, shorter words - w7: unexplained or banned words: targeted therapy - q8: unexplained or banned words: HER2 - w8: unexplained or banned words: MET - q9: reading grade 11.6, needs 8 or lower: shorter sentences, shorter words - w9: reading grade 13.1, needs 8 or lower: shorter sentences, shorter words - p0.a: reading grade 15.2, needs 8 or lower: shorter sentences, shorter words - p0.r: unexplained or banned words: resistance LINES (id (kind): text): landing.h (headline): All five views agree your cancer shrank on the daily pill after three months, showing the medicine is working for your EGFR gene change. landing.s (landing): Your September 2026 CT scan shows the tumors shrank on osimertinib (the daily pill you started in June 2026), with mild side effects like a rash and you are up and about most of the day. The Standard of Care and Molecular views say the treatment is doing what doctors expect for lung cancer with your EGFR exon 19 deletion that has spread. The call to make with your cancer doctor: whether to keep taking the pill with regular scans only, or to add support for side effects now and plan ahead for what tests to run when the cancer starts growing again. q0 (question): When the cancer starts growing on osimertinib, what tests will you order to find out why it stopped working, like a blood test for tumor DNA or a new tissue biopsy? w0 (why): Different reasons the pill stops working need different next treatments, so knowing the testing plan helps you get ready for the next choice. q1 (question): Which clinical trials at your center are for people whose cancer grew on osimertinib, and could I join trials like NCT07100080 for a new drug after the pill fails or NCT04410796 that combines osimertinib with chemotherapy? w1 (why): New combinations and drugs in trials may work better than the usual next treatment when your cancer grows on osimertinib. q2 (question): How often will you check my response with CT scans while I take osimertinib, and what changes on the scan mean the cancer is growing versus still shrinking? w2 (why): Your September 2026 scan showed the tumors shrank, so knowing the scan schedule and what counts as growth helps you know what to expect at each checkup. q3 (question): Does my PD-L1 level of 30 percent change the plan if osimertinib stops working, or does the EGFR gene change make the targeted pill more important than immunotherapy? w3 (why): Your tumor has both an EGFR change that targeted pills work on and a PD-L1 level that immunotherapy might help, so knowing which one drives the next choice helps you understand the order of treatments. q4 (question): Can you send me to a skin doctor now to manage my mild rash before it gets worse, or do we wait until it is more serious? w4 (why): Rash is a common side effect of osimertinib that can force you to lower the dose or stop the pill if not treated early, which could hurt how well it works. q5 (question): Would adding palliative care (a team that helps manage symptoms and improve quality of life) now help me feel better and stay strong during long term treatment with osimertinib? w5 (why): Palliative care helps manage symptoms and quality of life for people with cancer that has spread, even when treatment is working, and starting early is linked to better outcomes. q6 (question): Is the bone spot from the cancer stable on the scans, and when would you recommend radiation to that area to prevent pain or a broken bone? w6 (why): Cancer in the bones can cause pain or breaks, so knowing the monitoring plan and when to treat helps you prepare for and manage bone problems. q7 (question): Should I work with a nutrition expert and exercise program for cancer patients now to improve my diet and activity while on osimertinib? w7 (why): Research shows nutrition and exercise help people tolerate treatment better, reduce tiredness, and keep quality of life up during long term targeted therapy. q8 (question): If my cancer grows because of MET amplification (another gene change that helps the tumor grow), could I join trials like NCT07315113 for a new drug plus osimertinib or NCT05099172 for a drug that targets EGFR and HER2 changes? w8 (why): MET amplification is a common reason osimertinib stops working, and knowing which trials target this change helps you plan ahead for next options. q9 (question): At what point would you think about adding chemotherapy to osimertinib like in trial NCT04410796, or is the plan to keep me on osimertinib alone as long as it controls the cancer? w9 (why): Some trials combine osimertinib with chemotherapy from the start, but your tumors are shrinking on osimertinib alone, so the question is whether adding chemotherapy now helps or just causes more side effects. p0.a (argument): This view sees continuing osimertinib as the best fit for lung cancer with your EGFR exon 19 deletion and PD-L1 level of 30 percent, following national guidelines. You are already showing the tumors shrank after three months with mild side effects like a rash and you are up and about most of the day, which confirms this pill is the right pick and supports staying on it until the cancer starts growing. p0.r (discuss): What to ask about: Whether to keep taking osimertinib because it is working well with the tumors shrinking and only mild side effects, how often to get CT scans in the first months and then every two to three months, and when the cancer grows to get a new tissue biopsy to test why the pill stopped working so the next treatment fits the reason for resistance like chemotherapy combinations or other targeted drugs or clinical trials